A Penn-led study "BRCA locus-specific loss of heterozygosity in germline BRCA1- and BRCA2 carriers," published in Nature Communications this week, found a relationship between the genetics of breast and ovarian tumors with germline BRCA1/2 mutations and whether the tumor retains the normal copy of the BRCA1/2 gene, and risk for primary resistance to a common chemotherapy that works by destroying cancer cells’ DNA. Department co-authors include former residents Drs. Lyndsey Emery and Amanda Barrett, and faculty members Drs. Jennifer Morrissette and Michael Feldman.
Read the Department of Communications news release